Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 14/20 | 0.57 |
| ▸ | RAF1 | P04049 | 8/20 | 0.57 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | TPO | P07202 | 1/20 | 0.41 |
| ▸ | EPX | P11678 | 1/20 | 0.41 |
| ▸ | LPO | P22079 | 1/20 | 0.41 |
| ▸ | MST1R | Q04912 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11028241 | 0.83 | BRAF (0.51) | BRAFRAF1DDR2MST1REGFR | |
| SCHEMBL11032412 | 0.81 | BRAF (0.54) | BRAFRAF1DDR2MST1REGFR | |
| SCHEMBL1161163 | 0.81 | BRAF (0.54) | BRAFRAF1DDR2MST1REGFR | |
| SCHEMBL11029853 | 0.81 | BRAF (0.54) | BRAFRAF1DDR2MST1REGFR | |
| SCHEMBL1161282 | 0.81 | BRAF (0.54) | BRAFRAF1DDR2MST1REGFR | |
| SCHEMBL11025537 | 0.78 | BRAF (0.52) | BRAFRAF1DDR2MST1REGFR | |
| SCHEMBL11030333 | 0.75 | BRAF (0.62) | BRAFRAF1DDR2EGFR | |
| SCHEMBL1161084 | 0.75 | BRAF (0.57) | BRAFRAF1DDR2MST1R | |
| SCHEMBL1161129 | 0.74 | BRAF (0.53) | BRAFRAF1DDR2MST1REGFR | |
| SCHEMBL1161172 | 0.74 | BRAF (0.53) | BRAFRAF1DDR2MST1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| EP-2461869-B1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2013-08-21 | — | — | EP | disclosed |
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | MERCK PATENT GMBH (DE) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190654-A1 | NOVEL BICYCLIC UREA COMPOUNDS | CCNC, CCNI, CCNA1 | BRAF 582/4885RAF1 1266/4885DDR2 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.